87390 Infectious agent antigen detection by immunoassay technique, (eg, enzyme immunoassay [EIA], enzyme-linked immunosorbent assay [ELISA], immunochemiluminometric assay [IMCA]) qualitative or semiquantitative, multiple-step method; HIV-1

Name of the Procedure:

Infectious Agent Antigen Detection by Immunoassay Technique (e.g., Enzyme Immunoassay [EIA], Enzyme-Linked Immunosorbent Assay [ELISA], Immunochemiluminometric Assay [IMCA]) - Qualitative or Semiquantitative, Multiple-Step Method; HIV-1

Summary

This procedure detects the presence of specific antigens from infectious agents, particularly HIV-1, using immunoassay techniques. These techniques include enzyme immunoassay (EIA), enzyme-linked immunosorbent assay (ELISA), and immunochemiluminometric assay (IMCA). The test results can be either qualitative (positive/negative) or semiquantitative (low/medium/high).

Purpose

The procedure aims to diagnose HIV-1 infection by detecting the presence of HIV-1 antigens in the blood. Early detection assists in timely treatment and management of the condition to improve patient outcomes and prevent transmission.

Indications

• Individuals with possible exposure to HIV-1.
• Patients presenting symptoms suggestive of HIV infection (e.g., fever, swollen lymph nodes, rash).
• Routine screening in high-risk populations (e.g., intravenous drug users, multiple sexual partners).
• Follow-up testing for individuals with inconclusive initial HIV screening results.

Preparation

• No special preparation or fasting is generally required.
• Patients should inform their healthcare provider of any current medications or underlying health conditions.
• Blood sample collection will be necessary.

Procedure Description

1. A blood sample is drawn from the patient.
2. The sample is processed in the laboratory where an immunoassay is performed.
3. In the laboratory, the sample is exposed to antibodies that specifically bind to HIV-1 antigens.
4. If HIV-1 antigens are present, the antibodies will bind, causing a measurable reaction (color change, light emission).
5. The reaction intensity is measured to provide qualitative or semiquantitative results.

Tools and Equipment:

• Blood collection tubes and needles.
• Immunoassay kits (EIA, ELISA, or IMCA).
• Laboratory equipment for analysis (e.g., spectrophotometer, luminometer).

Duration

The entire process, from blood sample collection to result interpretation, typically takes a few hours to a few days, depending on the laboratory capacity and technology used.

Setting

This procedure is usually performed in a laboratory setting. Blood sample collection can take place in a hospital, outpatient clinic, or physician’s office.

Personnel

• Phlebotomist (for blood sample collection).
• Laboratory technician or technologist (for performing the immunoassay).
• Pathologist or medical laboratory scientist (for result validation).

Risks and Complications

• Minor discomfort or bruising at the blood draw site.
• Rare risks include infection or excessive bleeding at the puncture site.

Benefits

• Early and accurate detection of HIV-1 infection.
• Enables timely initiation of antiretroviral therapy (ART).
• Helps prevent the spread of HIV-1 to others.

Recovery

• Patients can resume normal activities immediately after the blood draw.
• Follow-up appointments may be scheduled to discuss results and subsequent steps.

Alternatives

• Rapid HIV tests (usually qualitative and provide results within 30 minutes).
• Polymerase Chain Reaction (PCR) tests for HIV RNA (more sensitive but also more expensive and time-consuming).
• Western Blot or Immunofluorescence assay (IFA) as confirmatory tests.

Patient Experience

• The patient may feel a quick pinch during blood sample collection and slight discomfort at the puncture site.
• No significant pain or downtime is expected.
• Results discussion might cause anxiety; appropriate counseling and support should be provided.